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2.1. Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was manu-
ally removed using a small blade. The embryo was bisected and plated
onto irradiated human feeders (Detroit 551 HFF — 90,000/well in 4-
well) in 20% KSR medium with 20 ng/mL FGF added fresh (Amit et al.,
2000). CGH karyotyping and STR proﬁling were performed at the ﬁrst
cryobanking step from ICM outgrowths maintained on feeders. Cells
were then enzymatically passaged as single cells in M2 pluripotent
cell maintenance medium (Genea Biocells) and CGH/karyotyping re-
peated, immunoﬂuorescent pluripotent marker staining, pluritest and
sterility testing performed.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CGH analysis summary; Genea089 (passage 4) reporting a female cell line and no
abnormalities detected.
CGH summary
Sample name Genea089p4
Date reported 16th August 2012
Hybridisation balance Balanced hybridization was observed for all
chromosomes, relative to reference DNA
Copy number change No copy number changes above 400 kb were detected
Interpretation Female cell line — no abnormalities detected
Table 2
STR proﬁle; Genea089 (passage 4) demonstrating female allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D1
GENEA089p4 14,15 29,31 10 11,15 17,18 6,9 8,1
Fig. 1. Pluripotency validation of Genea089. A) Immunoﬂuorescent staining (10×) of plur
enzymatic). B) Quantitation of expression of pluripotent markers. C) PluriTest Pluripoten
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1. ComparativeGenomicHybridisation (CGH) based chromosomal anal-
ysis: Passage 4; CGH was used to screen targeted regions of the ge-
nome for gains and losses associated with chromosomal imbalances
such as aneuploidy, deletions and duplications. CGH was performed
using SurePrint G3microarrays (8× 60K format)whichwere scanned
with the Agilent Scanner C and analysed using Genomic Workbench
Standard Edition 5.0 software (Agilent Technologies).
2. DNAProﬁling: Passage 4;DNA ‘ﬁngerprinting’wasperformedusing the
AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the cell
lines. https://www.thermoﬁsher.com/order/catalog/product/4322288.
Pluripotency assessment
1. Immunoﬂuorescence: Passage 8 (6 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1–60 #560121 1:150; SSEA4 #5603083S31
1
ipoten
cy (le1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
2. Pluritest: Passage 8 (6 on feeders, 2 enzymatic); RNA was collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).
2.3. Sterility testing
1. Mycoplasma: Passage 8 (6 on feeders, 2 enzymatic); testing was
performed as per manufacturer's instructions using the MycoAlert
Mycoplasma Detection Kit from LONZA
2. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell
Production Team.
3. Veriﬁcation and authentication
3.1. Ethics/consents
Ethics approval for the project (‘Derivation of human embryonic
stem cells from embryos identiﬁed through pre-implantation genetic
diagnosis to be affected by known genetic conditions’) was obtained
from the Genea Ethics Committee on 13 September 2005. Excess ART
embryoswere fully consented for stem cell derivation by all responsible
people through an informed consent process (signed de-identiﬁed
consent form can be provided upon request). Donors have received no
payment or ﬁnancial beneﬁts for their donation. Genea089 has been7 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
12 17,19 13,14 18,19 8,11 15 10,12 23,24
t cellmarkers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 8, 2
ft) and novelty (right) scores with Genea089 (passages 8, 2 enzymatic) outlined in black.
436 B. Dumevska et al. / Stem Cell Research 16 (2016) 434–436derived from a donated, fully commercially consented embryo, original-
ly created by assisted reproduction technology (ART) for the purpose of
procreation. The embryo was identiﬁed through pre-implantation
genetic diagnosis to be affected by a genetic mutation and was
declared excess to reproductive needs. Derivation was performed
under Australian National Health and Medical Research Council
(NHMRC) licence 309710. This licence was issued to GENEA on 7 May
2007. More information about the licence can be obtained from the
NHMRC webpage at http://www.nhmrc.gov.au/health-ethics/human-
embryos-and-cloning/database-licences-authorising-use-excess-art-
embryos.
3.2. PGD analysis conclusion
Mutation; expansion of CAG (41 CAG repeats) in HTT gene. Family
tree; Father has 41 repeats; b inherited from his Father. Huntington
Disease (HD) affected.
3.3. Morphology
The derived stem cell line, Genea089, morphologically displays ad-
herent monolayer of compact cells in well-deﬁned colonies with high
nuclear to cytoplasmic ratio and prominent nucleoli.
3.4. Genetic analysis
The cell line has been karyotyped and tested by CGH, which demon-
strated 46, XX karyotype (Table 1, Supplementary Fig. 1) consistent
with original derivation and pre-implantation genetic diagnosis(PGD). Analysis of STR markers showed Allele pattern consistent with
female genotype (Table 2, Supplementary Fig. 2).
3.5. Pluripotency
GENEA089 is pluripotent by;
1. Immunoﬂuorescence with 91% Nanog positive, 95% Oct4, 90% Tra1–
60 and 100% SSEA4 positive (Fig. 1A, quantiﬁed in B).
2. Pluritest with a Pluripotency score of 39.28 and Novelty score of 1.2
(Fig. 1C).
3.6. Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 3).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.013.
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